- Home
- QUBT vs MLYS Comparison
QUBT vs MLYS Comparison
Compare QUBT & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QUBT
- MLYS
- Stock Information
- Founded
- QUBT 2001
- MLYS 2019
- Country
- QUBT United States
- MLYS United States
- Employees
- QUBT N/A
- MLYS N/A
- Industry
- QUBT Computer Manufacturing
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- QUBT Technology
- MLYS Health Care
- Exchange
- QUBT Nasdaq
- MLYS Nasdaq
- Market Cap
- QUBT 2.7B
- MLYS 3.1B
- IPO Year
- QUBT N/A
- MLYS 2023
- Fundamental
- Price
- QUBT $15.66
- MLYS $40.00
- Analyst Decision
- QUBT Strong Buy
- MLYS Strong Buy
- Analyst Count
- QUBT 3
- MLYS 6
- Target Price
- QUBT $26.33
- MLYS $42.60
- AVG Volume (30 Days)
- QUBT 51.5M
- MLYS 1.3M
- Earning Date
- QUBT 11-10-2025
- MLYS 11-10-2025
- Dividend Yield
- QUBT N/A
- MLYS N/A
- EPS Growth
- QUBT N/A
- MLYS N/A
- EPS
- QUBT N/A
- MLYS N/A
- Revenue
- QUBT $263,000.00
- MLYS N/A
- Revenue This Year
- QUBT $20.32
- MLYS N/A
- Revenue Next Year
- QUBT $373.48
- MLYS N/A
- P/E Ratio
- QUBT N/A
- MLYS N/A
- Revenue Growth
- QUBT N/A
- MLYS N/A
- 52 Week Low
- QUBT $1.03
- MLYS $8.24
- 52 Week High
- QUBT $27.15
- MLYS $44.80
- Technical
- Relative Strength Index (RSI)
- QUBT 40.97
- MLYS 53.93
- Support Level
- QUBT $13.88
- MLYS $41.74
- Resistance Level
- QUBT $23.79
- MLYS $44.60
- Average True Range (ATR)
- QUBT 2.16
- MLYS 2.22
- MACD
- QUBT -0.77
- MLYS -0.83
- Stochastic Oscillator
- QUBT 19.76
- MLYS 46.44
About QUBT Quantum Computing Inc.
Quantum Computing Inc is an integrated photonics and quantum optics technology company that provides accessible and affordable quantum machines to the world today. Its products are designed to operate at room temperature and low power at an affordable cost. The Company's portfolio of core technologies and products offer capabilities in the areas of high-performance computing, artificial intelligence, and cybersecurity, as well as remote sensing applications.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.